Harvard Apparatus Regenerative Technology, Inc.

For the period ended Jun 30, 2025. Filed Aug 11, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 11, 2025

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

Three Months Ended · Six Months Ended
	June 30,		June 30,
	2025	2024	2025	2024
Product revenue	$317	$56	$362	$113
Operating expenses:
Cost of sales	302	13	335	25
Research and development	697	642	1,298	1,482
Sales and marketing	—	197	10	312
General and administrative	1,151	1,685	2,222	2,796
Total operating expenses	2,150	2,537	3,865	4,615
Operating loss	(1,833)	(2,481)	(3,503)	(4,502)
Other income (expense), net:
Interest income	7	—	20	—
Interest expense	(3)	(17)	(5)	(26)
Other income	6	—	6	—
Other income (expense), net	10	(17)	21	(26)
Net loss	$(1,823)	$(2,498)	$(3,482)	$(4,528)
Basic and diluted net loss per share	$(0.11)	$(0.18)	$(0.22)	$(0.32)
Weighted average common shares outstanding, basic and diluted	15,918,979	14,258,511	15,918,979	14,102,918
Comprehensive loss:
Net loss	$(1,823)	$(2,498)	$(3,482)	$(4,528)
Foreign currency translation adjustments	(1)	(21)	(1)	(22)
Comprehensive loss	$(1,824)	$(2,519)	$(3,483)	$(4,550)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.